TW201737919A - 治療癌症的方法 - Google Patents

治療癌症的方法 Download PDF

Info

Publication number
TW201737919A
TW201737919A TW106112194A TW106112194A TW201737919A TW 201737919 A TW201737919 A TW 201737919A TW 106112194 A TW106112194 A TW 106112194A TW 106112194 A TW106112194 A TW 106112194A TW 201737919 A TW201737919 A TW 201737919A
Authority
TW
Taiwan
Prior art keywords
cancer
compound
hepatocellular carcinoma
treating
pharmaceutically acceptable
Prior art date
Application number
TW106112194A
Other languages
English (en)
Chinese (zh)
Inventor
安東尼奧 莫斯奇塔
耶穌‧瑪麗亞‧巴尼亞萊斯 阿蘇兒美蒂
路易斯‧布罕達‧費爾南德斯 德‧佩羅拉
瑪麗亞‧耶穌‧佩魯戈裡亞 蒙提爾
歐亨‧埃里切 阿斯帕倫
Original Assignee
英特賽普醫藥品公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 英特賽普醫藥品公司 filed Critical 英特賽普醫藥品公司
Publication of TW201737919A publication Critical patent/TW201737919A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW106112194A 2016-04-13 2017-04-12 治療癌症的方法 TW201737919A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662321816P 2016-04-13 2016-04-13
US201762468259P 2017-03-07 2017-03-07

Publications (1)

Publication Number Publication Date
TW201737919A true TW201737919A (zh) 2017-11-01

Family

ID=60039308

Family Applications (1)

Application Number Title Priority Date Filing Date
TW106112194A TW201737919A (zh) 2016-04-13 2017-04-12 治療癌症的方法

Country Status (10)

Country Link
US (2) US10369160B2 (enExample)
EP (1) EP3442946A4 (enExample)
JP (1) JP6968821B2 (enExample)
KR (1) KR102377338B1 (enExample)
CN (1) CN109071452A (enExample)
AU (1) AU2017249226B2 (enExample)
CA (1) CA3020698A1 (enExample)
IL (1) IL262342B (enExample)
TW (1) TW201737919A (enExample)
WO (1) WO2017180577A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201832768A (zh) * 2017-03-07 2018-09-16 英特賽普醫藥品公司 治療癌症的方法
EP3723811A4 (en) * 2017-12-14 2021-09-01 Tarveda Therapeutics, Inc. TARGETING HSP90 CONJUGATES AND FORMULATIONS OF THE LATTER
CN108680696B (zh) * 2018-05-15 2020-06-30 南京正大天晴制药有限公司 一种奥贝胆酸起始物料的检测方法
US20230146782A1 (en) * 2019-08-06 2023-05-11 Du Jessica Xinyun Deoxycholic acid compounds, pharmaceutical compositions and uses thereof
JP2022552655A (ja) 2019-10-07 2022-12-19 キャリーオペ，インク． Ｇｐｒ１１９アゴニスト
MX2022010548A (es) 2020-02-28 2022-09-23 Kallyope Inc Agonistas de gpr40.
MX2022014505A (es) 2020-05-19 2022-12-13 Kallyope Inc Activadores de la ampk.
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators
CN113143936B (zh) * 2021-02-10 2022-03-25 北京蕴汇医药科技有限公司 鹅去氧胆酸或其衍生物在制备egfr和/或stat3的抑制剂中的用途
CN114306349A (zh) * 2022-01-07 2022-04-12 北京蕴汇医药科技有限公司 鹅去氧胆酸或其衍生物制备协同预防或治疗与egfr相关疾病药物的用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1392714T3 (da) 2001-03-12 2006-01-09 Intercept Pharmaceuticals Inc Steroider som agonister for FXR
WO2003080803A2 (en) 2002-03-21 2003-10-02 Smithkline Beecham Corporation Methods of using farnesoid x receptor (fxr) agonists
ITMI20050912A1 (it) 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
DK2040713T3 (da) 2006-06-27 2014-09-29 Intercept Pharmaceuticals Inc Galdesyrederivater som fxr-ligander til forebyggelsen eller behandlingen af fxr-medierede sygdomme eller tilstande
US8338628B2 (en) 2007-08-28 2012-12-25 City Of Hope Method of synthesizing alkylated bile acid derivatives
HUE039171T2 (hu) 2008-11-19 2018-12-28 Intercept Pharmaceuticals Inc TGR5 modulátorok és azok alkalmazási eljárása
WO2013037482A1 (en) * 2011-09-15 2013-03-21 Phenex Pharmaceuticals Ag Farnesoid x receptor agonists for cancer treatment and prevention
NZ707389A (en) 2012-10-26 2018-08-31 Intercept Pharmaceuticals Inc Process for preparing bile acid derivatives
WO2014085474A1 (en) * 2012-11-28 2014-06-05 Intercept Pharmaceuticals, Inc. Treatment of pulmonary disease
US9814733B2 (en) * 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
CN105377870B (zh) * 2013-05-14 2018-04-03 英特塞普特医药品公司 作为法尼醇x受体调节剂的胆汁酸的11‑羟基衍生物及其氨基酸共轭物
WO2015183794A1 (en) * 2014-05-27 2015-12-03 City Of Hope Tgr5 agonist complexes for treating diabetes and cancer
PE20180690A1 (es) * 2015-04-27 2018-04-23 Intercept Pharmaceuticals Inc Composiciones de acido obeticolico y metodos de uso
AU2016326428A1 (en) * 2015-09-21 2018-04-12 Intercept Pharmaceuticals, Inc. Methods of promoting hepatic regeneration

Also Published As

Publication number Publication date
IL262342A (en) 2018-11-29
US20190298742A1 (en) 2019-10-03
EP3442946A4 (en) 2019-12-04
WO2017180577A1 (en) 2017-10-19
JP6968821B2 (ja) 2021-11-17
US10369160B2 (en) 2019-08-06
CA3020698A1 (en) 2017-10-19
AU2017249226A1 (en) 2019-08-22
CN109071452A (zh) 2018-12-21
JP2019511550A (ja) 2019-04-25
KR102377338B1 (ko) 2022-03-21
KR20180129925A (ko) 2018-12-05
IL262342B (en) 2022-08-01
US20170296556A1 (en) 2017-10-19
AU2017249226B2 (en) 2021-07-15
EP3442946A1 (en) 2019-02-20

Similar Documents

Publication Publication Date Title
US10369160B2 (en) Methods of treating cancer
WO2021263180A1 (en) Use of oxygenated cholesterol sulfates for cancers and non-cancerous transformations related to epstein-barr virus
EP3411058B1 (en) Combination therapy with a6 and paclitaxel for the treatment of ovarian cancer
DK202100069U1 (da) Apparat og fremgangsmåde til medicinlevering på plejestedet
US20230048576A1 (en) Compounds for the treatment of neuropathic pain
TW201832768A (zh) 治療癌症的方法
EP4096749A1 (en) Apparatus for and method in direct drug infusion using a label as a hanger
US20180256600A1 (en) Methods of treating cancer
US20220184099A1 (en) Methods of using obeticholic acid
US20260102466A1 (en) ß-DEFENSIN-2 PEPTIDE FOR INHIBITING CELL GROWTH OF COLON CANCER
US20240050515A1 (en) Methods and compositions for treating cd44+ cancers
US20230272103A1 (en) Cd44-modulating compositions for methods for treating cancers and ascites
WO2020232445A1 (en) Modulators of pyrimidine nucleotide biosynthetic pathways
US12350241B1 (en) Method for inhibiting proliferation of cancer cells
HK40010220A (en) Methods of treating cancer
CA2925305A1 (en) Combination therapy with a6 and chemotherapeutic agents for the treatment of cancer
HK40001457B (en) Combination therapy with a6 and paclitaxel for the treatment of ovarian cancer
HK40001457A (en) Combination therapy with a6 and paclitaxel for the treatment of ovarian cancer
HK1260434A1 (en) Methods of treating cancer